Landmark Diovan® (valsartan) mega-trial proves life-saving benefits for heart attack sufferers
Diovan is the only cardiovascular agent ever demonstrated by a head-to-head trial to have all the proven benefits of an ACE inhibitor, captopril, in patients following a heart attack.
VALIANT further strengthens the profile of Diovan in cardiovascular disease across key standard of care measures like cardiovascular protection, tolerability, blood pressure lowering efficacy and patient persistency with therapy1
Orlando, Florida, 10 November 2003 - The fastest-growing branded high blood pressure treatment in the world, Diovanâ (valsartan), is also a potentially life-saving treatment after a heart attack, according to the findings of VALIANT, a major new study announced today at the American Heart Association Scientific Sessions 2003 and published online in the New England Journal of Medicine. VALIANT (VALsartan In Acute myocardial iNfarcTion) is the largest long-term study ever conducted in people who have survived a heart attack. This critical new data set helps establish Diovan as a highly desirable and powerful first-line option for an increasingly wide patient population.
Please find full press release under the following link:
